Customised design of antisense oligonucleotides targeting EGFR driver mutants for personalised treatment of non-small cell lung cancer
Customised design of antisense oligonucleotides targeting EGFR driver mutants for personalised treatment of non-small cell lung cancer
Trinh T. T. Tran,a,l Cao Dai Phung,a,l Brendon Z. J. Yeo,a,l Rebecca C. Prajogo,a Migara K. Jayasinghe,a,b Ju Yuan,c Daniel S. W. Tan,c,d,e,f ,g Eric Y. M. Yeo, Boon Cher Goh,a,b Wai Leong Tam,b,c,h,i,∗∗ and Minh T. N. Lea,j,k,∗
Summary
Background Tyrosine kinase inhibitors (TKIs) are currently the standard therapy for patients with non-small cell lung cancer (NSCLC) bearing mutations in epidermal growth factor receptor (EGFR). Unfortunately, drug-acquired resistance is inevitable due to the emergence of new mutations in EGFR. Moreover, the TKI treatment is associated with severe toxicities due to the unspecific inhibition of wild-type (WT) EGFR. Thus, treatment that is customised to an individual’s genetic alterations in EGFR may offer greater therapeutic benefits for patients with NSCLC.
( Full Article : https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(24)00392-X/fulltext )